浏览全部资源
扫码关注微信
胆红素上调PPARα/CPT1A降低Huh7细胞对索拉非尼的敏感性
Bilirubin impairs the sorafenib sensitivity in Huh7 cells through fatty acid oxidation by up-regulating PPARα/CPT1A
- 陆军军医大学学报 2022年44卷第16期 页码：1606-1612
- 作者机构：
400038 重庆，陆军军医大学(第三军医大学)第一附属医院肿瘤科
- 作者简介：
[梁后杰，E-mail: lianghoujie@sina.comLIANG Houjie, E-mail: lianghoujie@sina.com
- 基金信息：国家自然科学基金青年科学基金项目(81803028)
DOI：10.16016/j.2097-0927.202201233
中图分类号： R735.7;R963;R979.1收稿：2022-01-24，
修回：2022-04-09，
纸质出版：2022-08-30
- 稿件说明：
移动端阅览
谭君, 张弛, 董严, 等. 胆红素上调PPARα/CPT1A降低Huh7细胞对索拉非尼的敏感性[J]. 陆军军医大学学报, 2022,44(16):1606-1612.
Jun TAN, Chi ZHANG, Yan DONG, et al. Bilirubin impairs the sorafenib sensitivity in Huh7 cells through fatty acid oxidation by up-regulating PPARα/CPT1A[J]. Journal of Army Medical University, 2022, 44(16): 1606-1612.
谭君, 张弛, 董严, 等. 胆红素上调PPARα/CPT1A降低Huh7细胞对索拉非尼的敏感性[J]. 陆军军医大学学报, 2022,44(16):1606-1612. DOI： 10.16016/j.2097-0927.202201233.
Jun TAN, Chi ZHANG, Yan DONG, et al. Bilirubin impairs the sorafenib sensitivity in Huh7 cells through fatty acid oxidation by up-regulating PPARα/CPT1A[J]. Journal of Army Medical University, 2022, 44(16): 1606-1612. DOI： 10.16016/j.2097-0927.202201233.
摘要
目的
2
观察胆红素(bilirubin，Bil)对索拉非尼(sorafenib，Sor)治疗肝癌效果的影响，并探讨其可能机制。
方法
2
体外实验：用不同浓度的Sor(0、2、4、8、16、32 μmol/L)、Bil(0、2.5、5、10、20、40 μmol/L)及不同浓度Sor+Bil(20 μmol/L)培养Huh7细胞系不同时间(24、48、72 h)后，通过CCK-8法检测细胞活力。采用Sor(4 μmol/L)、Bil(20 μmol/L)、Sor(4 μmol/L)+Bil(20 μmol/L)处理Huh7细胞，48 h后用流式细胞仪检测细胞周期，14 d后通过克隆形成实验检测药物对细胞增殖的影响。体内实验：取16只裸鼠构建Huh7细胞异种移植瘤模型，按S型抽样方法将裸鼠分为Con组、Bil组(25 mg·kg
-1
·d
-1
)、Sor(15 mg·kg
-1
·d
-1
)组、Bil(25 mg·kg
-1
·d
-1
)+Sor(15 mg·kg
-1
·d
-1
)组，每组各4只，并进行相应处理。通过Western blot和实时荧光定量PCR(RT-qPCR)检测各组过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptor
PPARα)、肉毒碱棕榈酰基转移酶1A(carnitine palmityl transferase 1A
CPT1A)的表达量。加入CPT1A抑制剂乙莫克舍(etomoxir，Eto)后，通过CCK-8、克隆形成实验验证Bil削弱Sor对肝癌细胞的增殖抑制与PPARα/CPT1A的相关性。
结果
2
CCK-8结果显示，Sor对Huh7细胞的增殖抑制效应呈现剂量和时间依赖(
P
<
0.05)，Bil对Huh7细胞活力没有明显影响(
P
>
0.05)。与单独Sor处理组相比，Bil+Sor组细胞增殖活力增加，细胞克隆数目较多(
P
<
0.05)，细胞在S期的数目减少(
P
<
0.05)。体内实验结果显示：Sor组肿瘤体积和质量小于Con组(
P
<
0.05)，Bil+Sor组肿瘤体积和质量大于Sor组(
P
<
0.05)。Western blot和RT-qPCR结果显示：与Sor组相比，Bil+Sor组PPARα、CPT1A的表达增多(
P
<
0.05)。与Bil+Sor组相比，加入Eto后
Bil+Sor+Eto组细胞增殖活力降低(
P
<
0.05)，细胞克隆数目减少(
P
<
0.05)。
结论
2
胆红素通过PPARα/CPT1A介导脂肪酸氧化削弱索拉非尼的抗肿瘤效果。
Abstract
Objective
2
To observe the effect of bilirubin (Bil) on sorafenib (Sor) in the treatment of liver cancer and explore the involved molecular mechanisms.
Methods
2
In vitro
Huh7 cells were treated with different concentration of Sor (0
2
4
8
16
32 μmol/L)
of Bil (0
2.5
5
10
20
40 μmol/L) and of Sor (0
2
4
8
16
32 μmol/L) +Bil (20 μmol/L) for 24
48 and 72 h. Cell viability was detected by CCK-8 assay. Huh7 cells were treated with Sor (4 μmol/L)
Bil (20 μmol/L) and Sor (4 μmol/L)+Bil (20 μmol/L)
cell cycle was detected by flow cytometry after 48 h
and the effects of drugs on cell proliferation were detected by clone formation assay after 14 d.
In vivo
16 mice bearing xenografts of Huh7 cells were divided into Con group
Bil group (25 mg·kg
-1
·d
-1
)
Sor group (15 mg·kg
-1
·d
-1
) and Bil(25 mg·kg
-1
·d
-1
)+Sor(15 mg·kg
-1
·d
-1
) group (
n
=4)
according to the S type sampling method. The expression levels of peroxisome proliferator-activated receptor (PPARα) and carnitine palmityl transferase 1A (CPT1A) were detected by Western blotting and real time PCR. After etomoxir (Eto)
the inhibitor of CPT1A
was added
CCK-8 and clone formation assay were used to verify the mechanisms correlated with PPARα/CPT1A.
Results
2
CCK-8 results showed that the inhibitory effect of Sor on Huh7 cells was in a dose and time-dependent manner (
P
<
0.05)
and Bil had no significant effect on Huh7 cells (
P
>
0.05). Compared with Sor group
the cell proliferation in Bil+Sor group was increased (
P
<
0.05)
the relative cell colony formation rate was grown (
P
<
0.05)
and the number of cells in S phase was decreased (
P
<
0.05).
In vivo
results showed that the tumor volume and weight of Sor group were lower than that of Con group (
P
<
0.05)
and the tumor volume and weight of Bil+Sor group were higher than those of Sor group (
P
<
0.05). Western b
lotting and RT-qPCR results showed that PPARα and CPT1A expression levels were increased in Bil+Sor group compared with Sor group (
P
<
0.05). After Eto was added
the cell proliferation and the relative cell clone formation rate of Bil+Sor+Eto group were decreased compared with Bil+Sor group (
P
<
0.05).
Conclusion
2
Bil impairs the antitumor effects of sorafenib treatment in hepatocellular carcinoma through fatty oxidation by up-regulating PPARα/CPT1A.
关键词
Keywords
references
SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GlOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA A Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
ZIOGAS I A, TSOULFAS G. Evolving role of sorafenib in the management of hepatocellular carcinoma[J]. World J Clin Oncol, 2017, 8(3): 203-213. DOI: 10.5306/wjco.v8.i3.203.
HAMOUD A R, WEAVER L, STEC D E, et al . Bilirubin in the liver-gut signaling axis[J ] . Trends Endocrinol Metab, 2018, 29(3): 140-150. DOI: 10.1016/j.tem.2018.01.002.
STEC D E, JOHN K, TRABBIC C J, et al . Bilirubin binding to PPARα inhibits lipid accumulation[J ] . PloS ONE, 2016, 11(4): e0153427. DOI: 10.1371/journal.pone.0153427.
KUO Y H, WANG J H, HUNG C H, et al . Albumin-bilirubin grade predicts prognosis of HCC patients with sorafenib use[J ] . J Gastroenterol Hepatol, 2017, 32(12): 1975-1981. DOI: 10.1111/jgh.13783.
NGUYEN T T H, NGUYEN V H, NGUYEN V H, et al . Role of baseline albumin-bilirubin grade on predict overall survival among sorafenib-treated patients with hepatocellular carcinoma in Vietnam[J ] . Cancer Control, 2019, 26(1): 1073274819865269. DOI: 10.1177/1073274819865269.
TADA T, KUMADA T, TOYODA H, et al . Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic[J ] . J Gastroenterol Hepatol, 2019, 34(6): 1066-1073.DOI: 10.1111/jgh.14564.
FAUBERT B, SOLMONSON A, DEBERARDINIS R J. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487): eaaw5473. DOI: 10.1126/science.aaw5473.
WANG Y G, XIA Y, LU Z M. Metabolic features of cancer cells[J]. Cancer Commun, 2018, 38(1): 65. DOI: 10.1186/s40880-018-0335-7.
BENSINGER S J, CHRISTOFK H R. New aspects of the Warburg effect in cancer cell biology[J]. Semin Cell Dev Biol, 2012, 23(4): 352-361. DOI: 10.1016/j.semcdb.2012.02.003.
KOPPENOL W H, BOUNDS P L, DANG C V. Otto Warburg's contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11(5): 325-337. DOI: 10.1038/nrc3038.
CAIRNS R A, HARRIS I S, MAK T W. Regulation of cancer cell metabolism[J]. Nat Rev Cancer, 2011, 11(2): 85-95. DOI: 10.1038/nrc2981.
CHENG S T, WANG G, WANG Y, et al . Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer [J ] . Clin Sci (lond), 2019, 133(15): 1745-1758. DOI: 10.1042/CS20190587..
SENNI N, SAVALL M, CABRERIZO GRANADOS D, et al . Β-catenin-activated hepatocellular carcinomas are addicted to fatty acids[J ] . Gut, 2019, 68(2): 322-334. DOI: 10.1136/gutjnl-2017-315448.
RICCIARDI M R, MIRABILⅡ S, ALLEGRETTI M, et al . Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias[J ] . Blood, 2015, 126(16): 1925-1929. DOI: 10.1182/blood-2014-12-617498.
MONTAGNER A, POLIZZI A, FOUCHÉ E, et al . liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFlD[J ] . Gut, 2016, 65(7): 1202-1214. DOI: 10.1136/gutjnl-2015-310798.
GORDON D M, BLOMQUIST T M, MIRUZZI S A, et al . RNA sequencing in human HepG2 hepatocytes reveals PPAR-α mediates transcriptome responsiveness of bilirubin[J ] . Physiol Genomics, 2019, 51(6): 234-240. DOI: 10.1152/physiolgenomics.00028.2019.
LOPASCHUK G D, WALL S R, OLLEY P M, et al . Etomoxir, a carnitine palmitoyltransferase Ⅰ inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine[J ] . Circ Res, 1988, 63(6): 1036-1043. DOI:10.1161/01.res.63.6.1036.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
